ArticleJournal of intensive care2020
Clinical outcomes of empirical high-dose meropenem in critically ill patients with sepsis and septic shock: a randomized controlled trial.
Article in Journal of intensive care, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03344627 (Clinical Outcome Study of High-dose Meropenem in Sepsis and Septic Shock Patients), which is not on this map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Clinical Outcome Study of High-dose Meropenem in Sepsis and Septic Shock Patients
Who cites it
20 citing papers in PubMed, 28 citations in OpenAlex.
- Extended vs Intermittent Infusion of Meropenem with Colistimethate Sodium and Risk of Acute Kidney Injury in Critically Ill Patients: A Propensity Score-Matched Retrospective Cohort Study.Infection and drug resistance · 2026Article
- High-dose versus standard-dose intermittent meropenem in critically ill patients: An observational cohort study.Annals of intensive care · 2026Article
- Initial Meropenem Plasma Concentration and Its Correlation with Sepsis Mortality: A Real-World Retrospective Study.Infection and drug resistance · 2025Article
- Effect of Meropenem on Conjugative Plasmid Transfer inInternational journal of molecular sciences · 2024Article
- Article
- Fever lasting 48 hours as a predictive factor of ESBL-producing bacteria in non-critically ill patients with urinary tract infection.Scientific reports · 2024Article
- Predictors of Treatment Failure and Mortality among Patients with Septic Shock Treated with Meropenem in the Intensive Care Unit.The Malaysian journal of medical sciences : MJMS · 2024Article
- Multistate modeling for survival analysis in critically ill patients treated with meropenem.CPT: pharmacometrics & systems pharmacology · 2024Article
- Knowledge, attitudes, and practices among physicians and pharmacists toward antibiotic use in sepsis.Frontiers in medicine · 2024Article
- Biomarkers estimating baseline mortality risk for neonatal sepsis: nPERSEVERE: neonate-specific sepsis biomarker risk model.Pediatric research · 2023Article
- Article
- An Overview of Drug Delivery Nanosystems for Sepsis-Related Liver Injury Treatment.International journal of nanomedicine · 2023Review
- Antibiofilm effect of melittin alone and in combination with conventional antibiotics toward strong biofilm of MDR-MRSA and -Frontiers in microbiology · 2023Article
- Meropenem Pharmacokinetics and Target Attainment in Critically Ill Patients.Infection and drug resistance · 2023Article
- Optimizing Meropenem in Highly Resistant Klebsiella pneumoniae Environments: Population Pharmacokinetics and Dosing Simulations in Critically Ill Patients.Antimicrobial agents and chemotherapy · 2022Article
- Weaning of septic patients from the ventilator in the intensive care unit by attention approach to common antibiotic regimens.Journal of family medicine and primary care · 2022Article
- Population Pharmacokinetics of Meropenem in Critically Ill Korean Patients and Effects of Extracorporeal Membrane Oxygenation.Pharmaceutics · 2021Article
- Population Pharmacokinetics and Pharmacodynamics of Meropenem in Critically Ill Pediatric Patients.Antimicrobial agents and chemotherapy · 2021Article
- Evaluation of Empirical Meropenem Bolus Protocol inInternational journal of general medicine · 2021Article
- A New Method for Optimizing Sepsis Therapy by Nivolumab and Meropenem Combination: Importance of Early Intervention and CTL Reinvigoration Rate as a Response Marker.Frontiers in immunology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAppropriate antimicrobial dosing is challenging because of changes in pharmacokinetics (PK) parameters and an increase in multidrug-resistant (MDR) organisms in critically ill patients. This study aimed to evaluate the effects of an empirical therapy of high-dose versus standard-dose meropenem in sepsis and septic shock patients.
methodsWe performed a prospective randomized open-label study to compare the changes of modified sequential organ failure assessment (mSOFA) score and other clinical outcomes of the high-dose meropenem (2-g infusion over 3 h every 8 h) versus the standard-dose meropenem (1-g infusion over 3 h every 8 h) in sepsis and septic shock patients. Patients' characteristics, clinical and microbiological outcomes, 14 and 28-day mortality, vasopressor- and ventilator-free days, intensive care unit (ICU) and hospital-free days, percent of the time of antibiotic concentrations above the minimum inhibitory concentration (%T>MIC), and safety were assessed.
resultsSeventy-eight patients were enrolled. Median delta mSOFA was comparable between two groups (- 1 in the high-dose group vs. - 1 in the standard-dose group;
conclusionsEmpirical therapy with the high-dose meropenem presented comparable clinical outcomes to the standard-dose meropenem in sepsis and septic shock patients. Besides, subgroup analysis manifested superior microbiological cure rate in sepsis or septic shock patients admitted from ED.
trial registrationClinicalTrials.gov, NCT03344627, registered on November 17, 2017.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.